Skip to main content
Infectious Mortality in ARD

Infectious conditions are a significant cause of mortality in ARD. Among patients hospitali

Dr. John Cush RheumNow

2 years 3 months ago
Infectious Mortality in ARD Infectious conditions are a significant cause of mortality in ARD. Among patients hospitalized with an infection, we compared in-hospital and long-term (3-year) mortality between those with and without ARD. https://t.co/p4n5Los89F https://t.co/vUBLC9TDDG
Save the date! We’ll be covering #EULAR24! https://t.co/HGjP2SFyOp

Dr. John Cush RheumNow

2 years 3 months ago
Save the date! We’ll be covering #EULAR24! https://t.co/HGjP2SFyOp
Small-molecule Drugs to Treat Systemic Lupus Erythematosus

A metanalysis of randomized controlled trials (RCTs) on tre

Dr. John Cush RheumNow

2 years 3 months ago
Small-molecule Drugs to Treat Systemic Lupus Erythematosus A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs. https://t.co/ZYPZcfKrBD https://t.co/ZGYFNVgN0s
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?
A unique study in military medicine of 1.5 million ED visits reveals the dynamics of high-rank and high-power patients a

Eric Topol EricTopol

2 years 3 months ago
A unique study in military medicine of 1.5 million ED visits reveals the dynamics of high-rank and high-power patients and doctors, and the care they get/provide https://t.co/hbsUt1s9YR @ScienceMagazine @sdschwab @vini_singh_ https://t.co/RIjq4awgeR
Interferons and Lupus Subsets

In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights

Dr. John Cush RheumNow

2 years 3 months ago
Interferons and Lupus Subsets In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to the relationship between interferons and lupus, which affects up to 1.5 million Americans. https://t.co/eWnNqVUpK9 https://t.co/yNp4GYHYKu
Risk Factors for Hydroxychloroquine Retinopathy

A long-term hydroxychloroquine users study found that 2.7% developed r

Dr. John Cush RheumNow

2 years 3 months ago
Risk Factors for Hydroxychloroquine Retinopathy A long-term hydroxychloroquine users study found that 2.7% developed retinopathy, and identified risk factors as increasing age, female sex, chronic kidney disease stage 3+ and tamoxifen use. https://t.co/3HWWoCMXfI https://t.co/TuYgzRJEzR
Dr. Gregory Curfman, MD (Executive editor of JAMA) writes on the chronological legal progress of a lawsuit stemming from rare instances of atypical femoral fractures associated with bisphosphonate (alendronate) use. While alendronate was FDA approved in 1995 for the prevention and treatment of osteoporosis, and legal action was initiated in 2011, there is still no legal resolution to this issue. 
Antacids can Diminish Bone Density
  • EurekAlert!
Proton pump inhibitors (PPIs), a specific class of antacid drugs, are among the most widely used medications of all. They are frequently prescribed to many groups of patients, including those with rheumatism. PPIs are used to prevent the stomach problems that can arise from taking certain anti-inflammatory drugs.
Single center EHR study of 5 064 pts w/ pre-diabetes compared those starting metformin (1154) vs 13 877 non-users w/

Dr. John Cush RheumNow

2 years 3 months ago
Single center EHR study of 5 064 pts w/ pre-diabetes compared those starting metformin (1154) vs 13 877 non-users w/ ~4 yrs F/U. Incidence of future gout was lower w/ metformin use (7.1 vs 9.5/1000PYs; HR 0.68); with no change in SUA or CRP https://t.co/CXdcEdWXhW https://t.co/j0ktehf9Sm
2023 Top 3 paper from JAMA Derm - 122 plaque psoriasis pts (mild-mod w/ PASI=3.1) & low vit D levels (~14.9), Rx w/

Dr. John Cush RheumNow

2 years 3 months ago
2023 Top 3 paper from JAMA Derm - 122 plaque psoriasis pts (mild-mod w/ PASI=3.1) & low vit D levels (~14.9), Rx w/ PBO vs vit D 20 000 IU/wk x 4 mos during winter; no signif vit D Rx benefit for PASI, MD global, DLQI or 25-OH levels(< than expected) https://t.co/8W5abvydY6 https://t.co/rKJjkiHwC6
My Cancelled Lecture (5.11.2024)

In lieu of this weeks podcast, Dr. Jack Cush records his "Life Lessons (that keep cha

Dr. John Cush RheumNow

2 years 3 months ago
My Cancelled Lecture (5.11.2024) In lieu of this weeks podcast, Dr. Jack Cush records his "Life Lessons (that keep changing) in Rheumatology Lecture. A lecture recently cancelled because some of this content was objectionable? (I dont think so!) https://t.co/8iObw8cE5S https://t.co/k06P4mMwmD
Inflammatory Myositis market size was valued at ~$575 million USD in 2022 with 184,204 confirmed IMM cases in the 7MM. I

Dr. John Cush RheumNow

2 years 3 months ago
Inflammatory Myositis market size was valued at ~$575 million USD in 2022 with 184,204 confirmed IMM cases in the 7MM. In the USA there were 90,064 cases in 2022 https://t.co/uLtxOYGrLr https://t.co/W5TApBDV3C
Metanalysis of 26 reports and 195 juvenile Dermatomyositis pts (age 4.9 yrs) treated w/ JAK inhib (tofa, rux, & bari

Dr. John Cush RheumNow

2 years 3 months ago
Metanalysis of 26 reports and 195 juvenile Dermatomyositis pts (age 4.9 yrs) treated w/ JAK inhib (tofa, rux, & bari); Good improvement in 90%, 69% & 93%, respectively. JAK indication refractory skin dz (35%) or muscle involvement (29%). TIME FOR RCTs!! https://t.co/0aaLV7iCWR https://t.co/DLGRqqmIyX
×